Evaxion to present 2026 company milestones at Biotech Showcase conference in San Francisco next week
Evaxion (NASDAQ: EVAX) will present its 2026 company milestones at the Biotech Showcase in San Francisco on January 13, 2026.
Rhea-AI Summary
Evaxion (NASDAQ: EVAX) will present its 2026 company milestones at the Biotech Showcase in San Francisco on January 13, 2026.
CEO Helen Tayton-Martin will deliver the company update on Tuesday, January 13, 2026 at 2:00 PM PST / 11:00 PM CET on Track: Yosemite C (Ballroom Level). The Biotech Showcase runs January 12-14, 2026 and coincides with the J.P. Morgan Healthcare Conference; Evaxion plans stakeholder meetings and investor engagement throughout the week.
Contact: Mads Kronborg, Vice President Investor Relations & Communication, +45 53 54 82 96, mak@evaxion.ai.
Positive
- None.
Negative
- None.
Details
News Market Reaction – EVAX
On Jan 7, the day this news came out, EVAX closed 6.73% above the previous close.
Data tracked by StockTitan Argus for the Jan 7 session.
Key Figures
- Conference dates
- January 12–14, 2026
- Biotech Showcase conference schedule in San Francisco
- Company presentation date
- January 13, 2026
- Evaxion 2026 milestones and company update
- Presentation time PST
- 2:00pm PST
- Biotech Showcase presentation slot
- Presentation time CET
- 11:00pm CET
- Biotech Showcase presentation slot
Historical Context
-
MSD declined EVX‑B2 option, Evaxion retained global rights and seeks partner.
-
New CMV EVX‑V1 preclinical data showing immune responses and viral inhibition.
-
Published 2026 schedule for business updates and quarterly financial results.
-
Phase 2 EVX‑01 immune and biomarker data presented at SITC 2025.
-
Q3 2025 results with strong EVX‑01 data, EVX‑B3 deal and extended runway.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
ai-immunology medical
techbio technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
COPENHAGEN, Denmark, January 7, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will present at the Biotech Showcase conference taking place from January 12-14, 2026, in San Francisco, California. CEO Helen Tayton-Martin will present Evaxion’s 2026 company milestones and provide a company update on January 13, 2026.
The Biotech Showcase conference coincides with the J.P. Morgan Healthcare Conference and Evaxion will engage with stakeholders in San Francisco, including potential business partners, throughout the week.
Presentation details:
Date: Tuesday, January 13, 2026
Time: 2:00pm PST/11:00pm CET
Track: Yosemite C (Ballroom Level)
Contact information
Evaxion A/S
Mads Kronborg
Vice President, Investor Relations & Communication
+45 53 54 82 96
mak@evaxion.ai
About Evaxion
Evaxion is a pioneering TechBio company based upon its AI platform, AI-Immunology™. Evaxion’s proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Based upon AI-Immunology™, Evaxion has developed a clinical-stage oncology pipeline of novel personalized vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. Evaxion is committed to transforming patients’ lives by providing innovative and targeted treatment options. For more information about Evaxion and its groundbreaking AI-Immunology™ platform and vaccine pipeline, please visit our website.
Forward-looking statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “target,” “believe,” “expect,” “hope,” “aim,” “intend,” “may,” “might,” “anticipate,” “contemplate,” “continue,” “estimate,” “plan,” “potential,” “predict,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could,” and other words and terms of similar meaning identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including, but not limited to, risks related to: our financial condition and need for additional capital; our development work; cost and success of our product development activities and preclinical and clinical trials; commercializing any approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our product candidates; our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; government regulation; protection of our intellectual property rights; employee matters and managing growth; our ADSs and ordinary shares, the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on our business from other significant geopolitical and macro-economic events; and other uncertainties affecting our business operations and financial condition. For a further discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F and other filings with the US Securities and Exchange Commission (SEC), which are available at www.sec.gov. We do not assume any obligation to update any forward-looking statements except as required by law.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.